Items Tagged ‘tafinlar’

May 7, 2018

FDA Approves Tafinlar® + Mekinist® for Adjuvant Treatment of BRAF V600-mutant Stage III Melanoma


CancerConnect News: The US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.1 About Melanoma  Stage III melanoma includes cancers of any thickness that have spread to the […]

View full entry

Tags: adjuvant treatment, BRAF V600E, dabrafenib, mekinist, Melanoma, News, precision cancer medicines, stage III, tafinlar, trametinib, V600K mutations